Ossianix, Inc is a privately owned early-stage company that specializes in the development of Biotherapeutic products using the highly adaptable single domain VNAR antibody derived from sharks. The favorable biological and biophysical characteristics of the VNAR structure enable the swift production of exceptionally high-affinity products targeting various classes that have been challenging to address using conventional antibody methods or different frameworks. Additionally, the platform is well-suited for creating bispecific antibodies that can be easily engineered to produce products with unique properties for diseases with significant unmet medical needs.